CRBU Caribou Biosciences Inc.

20.17
-0.01  0%
Previous Close 20.18
Open 20.38
52 Week Low 15
52 Week High 32.645
Market Cap $1,209,551,932
Shares 59,970,843
Float 56,253,983
Enterprise Value $1,207,408,274
Volume 199,821
Av. Daily Volume 741,502
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
CB-010 (ANTLER)
B-Cell Non-Hodgkin Lymphoma
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
CB-012
Acute Myeloid Leukemia
Phase 1
Phase 1
IND filing expected in 2023.
CB-011
Multiple or Refractory Multiple Myeloma
Phase 1
Phase 1
IND filing expected in 2022.

Latest News

  1. BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's President and Chief Executive Officer, will present a company overview at the following upcoming investor conferences.

    •   Jefferies Gene Therapy/Editing Summit: Wednesday, October 27, 1:00-1:25 PM ET
    •   Barclays Gene Editing & Gene Therapy Summit: Monday, November 15, 9:30-9:55 AM ET

    Live webcasts of the presentations will be accessible via Caribou's website on the Events page. Archived copies of the webcasts will be available on the Caribou website for 30 days after the events.

    About Caribou's Novel Next-Generation

    BERKELEY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's President and Chief Executive Officer, will present a company overview at the following upcoming investor conferences.

    •   Jefferies Gene Therapy/Editing Summit: Wednesday, October 27, 1:00-1:25 PM ET

    •   Barclays Gene Editing & Gene Therapy Summit: Monday, November 15, 9:30-9:55 AM ET

    Live webcasts of the presentations will be accessible via Caribou's website on the Events page. Archived copies of the webcasts will be available on the Caribou website for 30 days after the events.

    About Caribou's Novel Next-Generation CRISPR Platform

    CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of the chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

    About Caribou Biosciences, Inc.

    Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

    For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

    "Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Contacts:

    Amy Figueroa, CFA

    Investor Relations and Corporate Communications

    afigueroa@cariboubio.com



    Investors:

    Elizabeth Wolffe, Ph.D. and Sylvia Wheeler

    Wheelhouse LSA

    lwolffe@wheelhouselsa.com 

    swheeler@wheelhouselsa.com 



    Media:            
     
    Greg Kelley

    Ogilvy

    gregory.kelley@ogilvy.com

    617-461-4023
     


    Primary Logo

    View Full Article Hide Full Article
  2. BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and the manufacture of gene and cell therapies.    

    "It is my pleasure to welcome Ran to our board of directors," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "Ran brings a wealth of strategic and operational expertise in the development of gene and cell therapies, from engineering and process development through manufacturing…

    BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed Ran Zheng to its board of directors. Ms. Zheng brings over 25 years of biotechnology industry leadership experience in biologics drug development with broad expertise in technical operations and the manufacture of gene and cell therapies.    

    "It is my pleasure to welcome Ran to our board of directors," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "Ran brings a wealth of strategic and operational expertise in the development of gene and cell therapies, from engineering and process development through manufacturing and supply chain management. We look forward to benefitting from her perspective and experience as we advance our chRDNA-edited allogeneic CAR-T and CAR-NK cell therapies for the potential treatment of challenging hematologic malignancies and solid tumors."

    "Caribou has developed an innovative and differentiated genome-editing technology that enables a pipeline of off-the-shelf allogeneic cell therapies designed to increase persistence and anti-tumor activity," said Ms. Zheng. "The work Caribou is doing to develop allogeneic cell therapies has the potential to make a real difference in the lives of patients with serious diseases. Caribou is clearly a leader in this field, and I am excited to join its board of directors."

    Ms. Zheng currently serves as chief executive officer and on the board of directors of Landmark Bio, a public benefit limited liability company that was formed to advance the development of transformative new medicines by translating today's cutting-edge research into tomorrow's breakthrough therapies. Landmark Bio focuses on the emerging technologies of cell and gene therapies, mRNA, and other novel modalities to enable and accelerate drug development and biomedical innovation. Prior to joining Landmark Bio earlier this year, Ms. Zheng most recently served as chief technical officer at Orchard Therapeutics, a commercial-stage global gene therapy company specializing in hematopoietic stem cell-based gene therapies. In that role, Ms. Zheng led the technical operations organization and helped advance the company's product pipeline, including contributing to the approval of Libmeldy® therapy in Europe, the first gene therapy product for metachromatic leukodystrophy. Ms. Zheng has also held leadership positions at multiple biotechnology companies including Genzyme (now Sanofi) and Amgen. At Amgen, Ms. Zheng held positions of increasing responsibility in process development, clinical and commercial manufacturing, as well as supply chain, and played a key role in building differentiated capabilities in manufacturing for clinical supply and commercial product launch to enable speed to clinic and speed to market strategies for Amgen's innovative products. Ms. Zheng received an M.S. in microbial engineering from the University of Minnesota and a B.S. in biology from Beijing Forestry University.

    About Caribou's Novel Next-Generation CRISPR Platform

    CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of the chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

    About Caribou Biosciences, Inc.

    Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

    Forward-Looking Statements

    This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to Caribou's pipeline of cell therapies, potential treatments, and expectations regarding its business. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of current and future research and development programs, preclinical and clinical trials, as well as other risk factors described from time to time in Caribou's filings with the Securities and Exchange Commission, including its final prospectus filed on July 23, 2021. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

    For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

    "Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Media Contact:Investor Relations Contact:
    Greg KelleyElizabeth Wolffe, Ph.D. and Sylvia Wheeler
    OgilvyWheelhouse LSA
    gregory.kelley@ogilvy.comlwolffe@wheelhouselsa.com
    617-461-4023swheeler@wheelhouselsa.com



    Primary Logo

    View Full Article Hide Full Article
  3. BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat on Monday, October 4, 2021, at 5:00 pm ET at the Chardan Virtual 5th Annual Genetic Medicines Conference. Dr. Haurwitz will also be part of a panel discussion: "Gene Editing: Next-Generation Technologies Worth Watching" on Tuesday, October 5, 2021, at 12:00pm ET.

    The live webcast of the fireside chat will be accessible via Caribou's website on the Events page. An archived copy of the webcast will be available on the Caribou website for 30 days after…

    BERKELEY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will participate in a fireside chat on Monday, October 4, 2021, at 5:00 pm ET at the Chardan Virtual 5th Annual Genetic Medicines Conference. Dr. Haurwitz will also be part of a panel discussion: "Gene Editing: Next-Generation Technologies Worth Watching" on Tuesday, October 5, 2021, at 12:00pm ET.

    The live webcast of the fireside chat will be accessible via Caribou's website on the Events page. An archived copy of the webcast will be available on the Caribou website for 30 days after the event.

    About Caribou's Novel Next-Generation CRISPR Platform

    CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of the chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

    About Caribou Biosciences, Inc.

    Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

    "Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Media Contact:Investor Relations Contact:
    Greg KelleyElizabeth Wolffe, Ph.D. and Sylvia Wheeler
    OgilvyWheelhouse LSA
    gregory.kelley@ogilvy.comlwolffe@wheelhouselsa.com
    617-461-4023swheeler@wheelhouselsa.com


    Primary Logo

    View Full Article Hide Full Article
  4. Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares

    ANTLER Phase 1 clinical trial of CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma ongoing

    Expanded company's board of directors with appointment of Nancy Whiting, Pharm.D.

    BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported business highlights and financial results for the second quarter of 2021.

    "2021 has been a transformational year for Caribou, and we believe that our highly successful IPO speaks to the enormous…

    Completed upsized initial public offering of common stock, raising $349.6 million in gross proceeds including full exercise of underwriters' option to purchase additional shares

    ANTLER Phase 1 clinical trial of CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma ongoing

    Expanded company's board of directors with appointment of Nancy Whiting, Pharm.D.

    BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported business highlights and financial results for the second quarter of 2021.

    "2021 has been a transformational year for Caribou, and we believe that our highly successful IPO speaks to the enormous potential of the company's chRDNA technology to deliver innovative, transformative therapies for patients with devastating diseases," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "In July, we announced the dosing of the first patient in our ANTLER Phase 1 clinical trial evaluating our lead product candidate, CB-010, in relapsed or refractory B cell non-Hodgkin lymphoma. In addition to this program, we have three other wholly-owned allogeneic cell therapy product candidates in our pipeline, and we are collaborating with AbbVie to research and develop two additional allogeneic CAR-T programs for AbbVie using our Cas12a chRDNA technology."

    Business Highlights

    Dosed the first patient in Phase 1 clinical trial of CB-010. In July 2021, Caribou reported dosing the first patient in its ANTLER Phase 1 clinical trial of CB-010. The ANTLER trial is evaluating CB-010 in patients with relapsed or refractory B cell non-Hodgkin lymphoma (B-NHL), and initial data from the trial are expected in 2022.

    Completed upsized IPO raising $349.6 million in gross proceeds. In July 2021, Caribou completed its IPO, selling 19,000,000 shares of its common stock at a price to the public of $16.00 per share, for gross proceeds of $304.0 million. In August 2021, the underwriters fully exercised their option to purchase an additional 2,850,000 shares of common stock at the IPO price, increasing the total number of shares sold by Caribou in the IPO to 21,850,000 shares and the aggregate gross proceeds to $349.6 million. Aggregate net proceeds from the IPO, after deducting underwriting discounts and commissions and other offering expenses payable by Caribou, were $321.0 million.  

    Expanded Caribou's board of directors. In August 2021, Nancy Whiting, Pharm.D., was appointed to Caribou's board of directors. Dr. Whiting, who most recently served as executive vice president, corporate strategy, alliances and communication of Seagen, Inc., brings over 17 years of biotechnology industry expertise in drug and portfolio development as well as significant strategic leadership experience. Dr. Whiting joins Scott Braunstein, M.D., Andrew Guggenhime, Rachel Haurwitz, Ph.D., and Natalie Sacks, M.D., on Caribou's board of directors. In July 2021, Mr. Guggenhime assumed the roles of chair of the board of directors and chair of the audit committee.

    Published data demonstrating the significantly improved specificity of Caribou's proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology compared to all-RNA guides. In September 2021, Caribou and its collaborators published studies in an article entitled, "Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells," in the journal Molecular Cell.

    Upcoming Milestones

    CB-010: Caribou expects initial data from the ongoing ANTLER Phase 1 trial in patients with relapsed or refractory B-NHL in 2022. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells engineered using Cas9 chRDNA technology to introduce a CD19-specific CAR into the TRAC gene locus, thus eliminating expression of the T cell receptor to reduce the risk of graft versus host disease. The T cells are further modified to knock out the PDCD1 gene, preventing the expression of the PD-1 protein, to boost the persistence of CAR-T cell antitumor activity.

    CB-011: Caribou expects to file an Investigational New Drug (IND) application for its CB-011 program in 2022. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy derived from healthy donor T cells that is being developed as a potential treatment for relapsed or refractory multiple myeloma. Caribou is engineering healthy donor T cells using its proprietary Cas12a chRDNA technology to introduce a BCMA-specific CAR into the TRAC gene locus. In addition, Caribou utilizes an immune cloaking strategy designed to prevent rapid immune rejection of CB-011. This strategy comprises two edits: knockout of the endogenous B2M gene and site-specific insertion of a B2M–HLA-E fusion gene into the T cell genome.

    CB-012: Caribou expects to file an IND application for its CB-012 program in 2023. CB-012 is an allogeneic anti-CD371 CAR-T cell therapy derived from healthy donor T cells for the potential treatment of relapsed or refractory acute myeloid leukemia. CB-012 cells are engineered using Caribou's proprietary Cas12a chRDNA technology to introduce a fully-human CD371-specific CAR into the TRAC locus and to armor the cells to promote persistence.

    CB-020: Caribou expects to announce target selection for its CB-020 program in 2022. CB-020, a CAR-NK product candidate, is the lead program in Caribou's proprietary genome-edited iPSC-derived natural killer (iNK) cell therapy platform. Multiplex-edited CAR-NKs hold significant potential for treating a variety of solid tumor types.

    Second Quarter 2021 Financial Results

    Cash and cash equivalents: Caribou finished the second quarter of 2021 with cash and cash equivalents of $129.5 million. Cash and cash equivalents as of June 30, 2021, do not include $321.0 million in aggregate net proceeds from the company's IPO completed in July and August of 2021.

    Licensing and collaboration revenue: Revenue generated from Caribou's licensing and collaboration agreements was $1.5 million for the second quarter of 2021, compared to $8.5 million for the second quarter of 2020. The decrease was primarily due to revenues recognized pursuant to an exclusive license agreement the company entered into during the second quarter of 2020.

    R&D expenses: Research and development expenses increased by $4.7 million to $12.3 million in the second quarter of 2021, up from $7.6 million in the second quarter of 2020. The increase in research and development expenses was primarily due to an increase in costs associated with intellectual property license and assignment agreements, costs associated with pre-clinical programs, an increase in payroll and related expenses, an increase in the fair value of the Memorial Sloan Kettering Cancer Center (MSKCC) success payments liability, and an increase in facilities and other allocated expenses.

    G&A expenses: General and administrative expenses increased by $2.0 million to $5.1 million in the second quarter of 2021, up from $3.2 million in the second quarter of 2020. The increase in general and administrative expenses was primarily due to an increase in recruiting and personnel costs, legal and accounting services, and facilities and maintenance expenses.

    Net loss: Caribou reported a net loss of $14.3 million in the second quarter of 2021, compared with a net loss of $1.9 million for the second quarter of 2020.

    About Caribou Biosciences, Inc.

    Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited allogeneic immune cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. The therapies target cell surface antigens for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof-of-concept as well as additional emerging targets.

    For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

    "Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to Caribou's strategy, plans and objectives, and expectations regarding its clinical and preclinical development programs, including its timing expectations. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of current and future research and development programs, preclinical studies, and clinical trials, as well as other risk factors described from time to time in Caribou's filings with the Securities and Exchange Commission, including its final prospectus filed on July 23, 2021. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

    Caribou Biosciences, Inc.

    Media Contact:
    Caribou Biosciences, Inc.

    Investor Relations Contacts:
    Greg KelleyElizabeth Wolffe, Ph.D., and Sylvia Wheeler
    OgilvyWheelhouse LSA
    gregory.kelley@ogilvy.comlwolffe@wheelhouselsa.com
    617-461-4023swheeler@wheelhouselsa.com

    – more –

     
    Condensed Consolidated Balance Sheet Data
    (in thousands)
         
      June 30, December 31,
      2021 2020
         
    Cash and cash equivalents $129,524  $15,953 
    Total assets  158,397   36,046 
    Total liabilities  55,938   18,160 
    Convertible preferred stock  150,150   41,323 
    Total stockholders' (deficit)  (47,691)  (23,437)
         
         
    Condensed Consolidated Statement of Operations
    (in thousands, except share and per share data)
            
     Three Months Ended June 30, Six Months Ended June 30,
     2021 2020 2021 2020
            
    Licensing and collaboration revenue$1,476  $8,478  $3,062  $10,178 
    Operating expenses:       
    Research and development 12,327   7,580   22,491   16,221 
    General and administrative 5,113   3,153   9,709   6,641 
    Total operating expenses 17,440   10,733   32,200   22,862 
    Loss from operations (15,964)  (2,255)  (29,138)  (12,684)
    Other income (expense):       
    Interest income 46   11   50   153 
    Interest expense (2)  (5)  (8)  (8)
    Change in fair value of equity securities -   -   -   (733)
    Gain on extinguishment of PPP loan 1,584   -   1,584   - 
    Other income 25   327   42   348 
    Total other income (expense) 1,653   333   1,668   (240)
    Net loss before provision for income taxes (14,311)  (1,922)  (27,470)  (12,924)
    Benefit from income taxes -   (50)  -   (1,252)
    Net loss and comprehensive loss$(14,311) $(1,872) $(27,470) $(11,672)
    Net loss per share, basic and diluted$(1.39) $(0.22) $(2.78) $(1.38)
    Weighted-average common shares outstanding, basic and diluted 10,261,770   8,441,934   9,882,715   8,435,672 
            



    Primary Logo

    View Full Article Hide Full Article
  5. Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications

    BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data demonstrating that its proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology provides significantly improved specificity compared to all-RNA guides, thereby enabling high levels of intended genomic edits in cells while eliminating or minimizing inadvertent off-target events. Higher specificity is a key advantage in the development of therapeutics…

    Data published in Molecular Cell provide a mechanistic framework to explain the enhanced specificity and key differentiation of Caribou's proprietary chRDNA technology for therapeutic applications

    BERKELEY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today the publication of data demonstrating that its proprietary CRISPR hybrid RNA-DNA (chRDNA) guide technology provides significantly improved specificity compared to all-RNA guides, thereby enabling high levels of intended genomic edits in cells while eliminating or minimizing inadvertent off-target events. Higher specificity is a key advantage in the development of therapeutics and of critical importance in therapies that contain multiple genome edits.

    The data, which provide a mechanistic framework to elucidate the specificity of chRDNA guides, were published in an article entitled, "Conformational control of Cas9 by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells," in the journal Molecular Cell.

    "Caribou is currently developing unique allogeneic CAR-T cell therapies with multiple genome edits designed to enhance their persistence in patients," said Steve Kanner, Ph.D., Caribou's chief scientific officer. "By altering the position and number of DNA residues in our chRDNA guides, we readily achieve optimal on-target editing and minimize unintended off-target edits that may be problematic in therapeutic applications."

    "These data demonstrate that our chRDNA editing platform provides an efficient and highly customizable approach to develop sophisticated allogeneic CAR-T cells for the treatment of hematologic malignancies," said Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer. "The first of Caribou's multiplex-edited product candidates, CB-010, is being evaluated in an ongoing Phase 1 clinical trial in patients with relapsed or refractory B cell non-Hodgkin lymphoma and we look forward to initial clinical data in 2022."

    The studies in the Molecular Cell paper were part of a collaboration between Caribou and the laboratory of Martin Jinek, Ph.D., at the University of Zurich, Switzerland. Dr. Jinek is a co-founder of Caribou and a leader in the field of CRISPR.

    The Molecular Cell paper describes studies comparing the editing activity and specificity of Cas9 programed with either chRDNA or all-RNA guides at multiple independent genomic sites in human primary T cells. The data demonstrate that chRDNA guides enable highly specific Cas9-mediated editing, with little to no perturbation of on-target efficiency, while the all-RNA guides give rise to multiple unintended off-target editing events across the genome. The study also demonstrates that the number and location of DNA nucleotides in a chRDNA design can be tuned for each intended target site to allow for the maximal level of discrimination between on- and off-target sites. Structural analysis of target-bound Cas9-chRDNA complexes revealed that chRDNAs result in an altered geometry of the chRDNA and target DNA interface, and this alteration is accompanied by structural rearrangements of the Cas9 protein. These changes disfavor off-target DNA binding and modulate Cas9 cleavage activity to inhibit editing at off-target sites. The publication can be accessed here.

    (Donohoue, Pacesa, et al., September 2, 2021, Molecular Cell 81(17), 3637-3649.)



    About Caribou's Novel Next-Generation CRISPR Platform

    CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNAs (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of the chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

    About Caribou Biosciences, Inc.

    Caribou is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying the company's proprietary chRDNA technology toward the development of next-generation, genome-edited cell therapies. The company is developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors against cell surface targets for which autologous CAR-T cell therapeutics have previously demonstrated clinical proof of concept, as well as additional emerging targets.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding Caribou's expectations with respect to the higher specificity of genomic edits using its chRDNA technology and the timing and availability of clinical trial data. Management believes that these forward-looking statements are reasonable as and when made. However, no assurance can be given that the specificity of genomic edits in actual practice will match the results of published data or that clinical trial data will be available on the timing indicated, or at all. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress, and results of current and future research and development programs, preclinical studies and clinical trials, as well as other risk factors described from time to time in Caribou's filings with the Securities and Exchange Commission, including its final prospectus filed on July 23, 2021. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

    For more information about Caribou, visit www.cariboubio.com and follow the company @CaribouBio.

    "Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

    Caribou Biosciences, Inc.

    Media Contact:            
    Caribou Biosciences, Inc.

    Investor Relations Contact:
    Greg KelleyElizabeth Wolffe, Ph.D., and Sylvia Wheeler
    OgilvyWheelhouse LSA
    gregory.kelley@ogilvy.comlwolffe@wheelhouselsa.com
    617-461-4023swheeler@wheelhouselsa.com


    Primary Logo

    View Full Article Hide Full Article
View All Caribou Biosciences Inc. News